Effects of strengthened atorvastatin treatment on Hcy and NT-proBNP in patients with non-ST-segment ele-vation acute coronary syndrome / 中国基层医药

ABSTRACT

Objective To study effects of strengthened atorvastatin treatment on homocysteine( Hcy) and N-terminal B-type natriuretic peptide( NT-proBNP) in patients with non-ST-segment elevation acute coronary syndrome. Methods 120 patients with non-ST-segment elevation acute coronary syndrome were randomly divided into the two groups,the observation group(n=60 cases) and the control group(n=60 cases).The patients in the observation group were treated through the basis of conventional therapy plus atorvastatin 40mg/night treatment,while the patients in the control group were treated through the basis of conventional therapy plus atorvastatin 20mg/night treatment. They were all treated for two months.Plasma Hcy and NT-proBNP were detected before and after treatment.Results Hcy in the observation group and the control group before treatment were ( 25.5 ±8.6 )μmol/L and ( 26.3 ± 9.1)μmol/L,respectively,(10.3 ±4.7)μmol/L and (16.9 ±7.1)μmol/L after treatment.NT-proBNP in the obser-vation group and the control group before treatment were (374.7 ±39.2)ng/L and (359.6 ±36.1)ng/L,respective-ly,(127.4 ±15.3)ng/L and (237.1 ±24.3)ng/L after treatment.After treatment,plasma Hcy and NT-proBNP were significantly reduced than those before treatment and after treatment(P<0.05).During follow-up,the two groups showed no elevated liver enzymes and muscle enzymes and lead to withdrawal from happening.Conclusion Strength-ened atorvastatin treatment can significantly reduce Hcy and NT-proBNP in patients with non-ST-segment elevation acute coronary syndrome.